Skip to Content

 

Peace of Mind through Redefined Cancer Survelliance

Matrix-Bio is employing metabolite profiling to create powerful new cancer diagnostic tests that provide an instantaneous snapshot of a patient's metabolism. These tests will detect the presence and

reoccurrence of cancer and monitor treatment with greater accuracy, speed, and less discomfort to the patient than current testing methodologies.

 

 

Breast cancer is the second most common cancer in American women, claiming more than 41,000 lives each year. Many women at high risk live with constant worry. Once a woman is diagnosed with breast cancer, it never leaves her side even if it is in remission. Providing an alternative to fear in the form of more accurate, reliable tests for the detection and monitoring of breast cancer is what drives Matrix-Bio to excel in the emerging field of metabolite profiling.


With early detection, breast cancer is highly treatable and survivable. Yet current diagnostic procedures yield too many false positives, resulting in costly, unnecessary and painful biopsies. Founded in 2006, Matrix-Bio is an Indiana-based life science company focused on the development and commercialization of advanced metabolite profiling-based blood tests for early cancer detection, recurrence detection, and therapy monitoring that offer greater accuracy than current testing methodologies.


Led by company founder and chief scientific officer Daniel Raftery, Matrix-Bio has developed an advanced metabolite profiling platform technology that enables simple, yet highly accurate tests for early-stage cancer diagnosis, recurrence monitoring, and tracking the effects of chemotherapy while therapy is in progress. Specifically, the company has combined advanced methods in nuclear magnetic resonance (NMR) and mass spectrometry (MS), the "gold standards" for analyzing biomarkers in blood and urine. The resulting patent-pending technology enables the identification of biomarkers that indicate early-stage breast cancer and its recurrence after therapy. The sensitivity and specificity of Matrix-Bio's tests, which rely on blood rather than tissue samples, is significantly greater than current detection and monitoring tests, including mammography. By accurately and reliably detecting cancer at an early, more treatable stage, patients and their physicians have more treatment options, a better prognosis and the peace of mind this knowledge provides.


Matrix-Bio's MetaMarker-BCR test for breast cancer recurrence monitoring and MetaMarker-BCD test for early detection have the potential to be the first commercially available, metabolite-based tests for breast cancer in the world. The non-invasive nature of these tests, coupled with accuracy, reliability, cost, convenience and speed, will drive demand among patients, physicians and payers.


Matrix-Bio's goal is to be a leading provider of metabolite-based testing in the fast-growing molecular diagnostic testing market. While the company's initial focus is breast cancer, its novel technology shows great potential for detecting and monitoring several deadly cancers and other important diseases.

 For Investors

Matrix-Bio's goal is to be a leading provider of metabolite-based testing in the fast-growing molecular diagnostic testing market.
Matrix-Bio, Inc., is an Indiana-based life science company focused on the development and commercialization of advanced metabolite profiling-based blood tests for early cancer detection, recurrence detection, and chemotherapy monitoring that offer greater accuracy than current testing methodologies. The company's initial focus is breast cancer; however, its patent-pending platform for identifying small molecule biomarkers shows great potential for other cancers and diseases due to its sensitivity and specificity in detecting characteristic changes in the body's metabolism.
The company's first product is MetaMarker-BCR, an exceptionally accurate, reliable test for monitoring patients for the recurrence of breast cancer, an important concern for breast cancer survivors. The first test of its kind in the world, MetaMarker-BCR has significant market potential. Currently, there are 2.5 million women in the United States who have had breast cancer. 
Following the completion of their cancer treatment, women remain in the care of a medical oncologist for approximately three years for the express purpose of identifying a recurrence of cancer.
Because MetaMarker-BCR relies on a simple blood draw and not a tissue sample, the test is simple for medical practices to implement yet it is a powerful tool for detecting recurring cancer. MetaMarker-BCR will be followed by a powerful test for breast cancer screening.



What is metabolite profiling ?

Metabolite profiling is part of an emerging field of chemical and clinical analysis that identifies and measures changes in important small molecule metabolite species-also known as biomarkers-found in blood or urine. Matrix-Bio is working to turn metabolite profiling methods into specific diagnostic tests, so that through a simple blood test it is possible to detect disease in its very early stages with a high degree of accuracy. Metabolite profiling can be used to detect cancer, heart disease, diabetes and other diseases. It also can be used to monitor the recurrence of disease or how a patient is responding to treatment. Metabolite profiling offers great promise to caregivers and their patients.
How is Matrix-Bio using metabolite profiling for breast cancer?
Next to skin cancer, breast cancer is the most common form of cancer in women. Early detection is very often the key to survival. Matrix-Bio's simple blood test may revolutionize how breast cancer is diagnosed and how physicians monitor patients for recurrence of cancer and track the effects of therapy. Using metabolite profiling, MatrixBio is able to identify and measure changes in biomarkers, and in so doing, accurately and reliably detect early stage breast cancer and detect its recurrence after therapy.
Why is Matrix-Bio's metabolite profiling such as powerful tool for breast cancer detection?
When breast cancer is diagnosed in its early stages, the patient has more treatment options and chances of survival are higher. Matrix-Bio's metabolite profiling-based blood test is extremely accurate as it identifies and quantifies small molecule biomarkers in the blood that indicate breast cancer even in its earliest stages. This is an exciting, potentially life-saving advancement as breast cancer tumors can grow for six to eight years before being detected by mammography.
Does Matrix-Bio's metabolite profiling technology platform have other disease applications?
Although MatrixBio is currently focused on breast cancer, its patent-pending metabolite profiling technology platform can be leveraged to detect other cancers as well. This is good news for patients, physicians, and payers who want better, more accurate tests for deadly cancers.